🇺🇸 FDA
Patent

US 7759304

Targeting complement factor H for treatment of diseases

granted A61KA61K38/00A61P

Quick answer

US patent 7759304 (Targeting complement factor H for treatment of diseases) held by The Regents of the University of Colorado expires Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Jul 20 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/00, A61P, A61P1/04, A61P11/06